Subscribe Now!

Indoco Remedies - Growth Back on Track

-
 Indoco Remedies Ltd. - Company Overview
Twitter Handle: @shuchi_nahar

1. Company Profile

The company was established in 1947. Indoco is a small-sized pharma company engaged in manufacture, marketing and distribution of pharmaceutical products and services in the domestic & international markets. Through its nine marketing divisions viz. Indoco, Spade, Warren NexGen, Warren ACE, Warren Excel and Vision, Indoco Focus, Indoco CND, Spera and Institution the company serves a range of doctor specialties. Indoco has signed supply agreements with companies like Watson, Aspen and DSM to supply formulations to advanced and emerging markets.

Figure:1 Graph Showing Revenue Trend & Revenue Breakup

2. India formulations growth core to overall growth

Domestic formulations (~63% of FY20 revenues) grew at 6.5% CAGR in FY16-20. The subdued growth can be attributed to high concentration of acute therapies and one of the lowest MR productivities. With a market share of ~0.7% and overall rank of 29, the company is still a marginal player with some top brands in smaller categories like stemmatological.

3. Exports formulations slowly - back on track

Exports formulations (~27% of overall FY20 sales) have de-grown at 6.6% CAGR in FY16-20, undone by regulatory hurdles in developed markets. However, recent clearance from the UK-MHRA and lifting of warning letters from the USFDA for Goa plant II and III (plant I is still under warning letter) is likely to improve operating leverage for export formulations.

4. Revenue Mix – FY20

Figure:2 Pie Chart showing Revenue Mix

5. Research and Development

Indoco’s R&D Centre has a highly skilled team of around 400 scientists involved in the research and development of API, FDFs as well as Analytical Services. First time launch of Allogliptin under Aloja and Aloja-M for antidiabetic therapy in India. On the back of this launch and a lower antidiabetic portfolio size, the management expects double digit growth in this segment going ahead.

· One para IV launch scheduled for H2FY21for the US market.
· The company provided for 2.25 crore of extra bad debts in Q1FY21
· Baddi (Plant-3) utilisation level at 35% and has an Opex of 4 crore per quarter (including depreciation)
· Q1 expenses were down to lower travel expenses and higher US sales contribution.
· Q1FY21 gross margins (~70%) are sustainable, going ahead. Employee cost is likely to be stable for the rest of this fiscal. Other expenditure - Some savings in travel + promotional spend may continue, higher productivity in India business.
· Q2FY21 domestic sales will continue to be impacted.
· Business on track as compared to last year – April: 50%, May: 60- 65%, June: 80%, Currently: 90%

The Company enjoys a good position in the domestic market with 27 brands ranking amongst the top 5 positions in their respective sub-segments:

Figure:3 Table Showing Market Share%

6. Patent Application filed till date – Geographic Distribution

Out of the 68 API patent applications filed, 24 applications were accepted and granted. These include two Patents granted in Europe and one in US for Alogliptin (Europe) and Canagliflozin (Europe and USA) APIs, during the financial year 2019 – 20. Out of the 22 FDF patent applications filed, 10 applications were accepted and granted. Indoco’s R&D efforts received Indian Patents for formulation of Diclofenac and Quetiapine tablets. 

Figure:4 Table showing number of Patents filed and approved till date

7. Capex & Debt

Capex was Rs500m for FY20 and guided to in similar range for FY21. INDR has a gross debt of Rs2.6bn with long and short term borrowing at Rs1.4bn and 1.3bn. CAPEX cycle is over while its regulatory issues are behind. There could be a possibility of next few quarters to be inflection point for earnings recovery.
It has multiple triggers like
1) Increased focus on chronic products
2) Strong order book for EU
3) Launch of new products in US
4) Underutilized API capacity.

Long term debt - 144 crore, short term debt - 125 crore, cash - 10-12 crore. Capex over the next two to three years to be less than 50 crore. Gross block for overall API segment is  120 crore.

 

8. ANDA Filing

Company targets to file 5-6 ANDAs every year and have sizable filings in Injectables. With number of ANDAs and Dossiers awaiting approval, the future for the Regulated markets looks optimistic over the next two years. Regulated markets include UK, US, New Zealand, Germany, Spain and others. In Emerging markets it includes mainly Africa, Asia, LatAm and others. Indoco has approval of 12 ANDAs while it has pending approval for 44 ANDAs with US FDA.

  The company received approval for its ANDA for Olanzapine Tablets 2.5mg, 5mg, 7.5mg, 10mg, 15mg and 20mg.The company is planning to launch this product in the US in the second half through a marketing partner.

One of the company’s US partners received approval for Palonosetron injection ANDA, which was filed from the Goa Plant II. Launch of this product has been planned in 2QFY21. Launch quantities of Tranexamic injections (June’20) and Zolendronic injections (July’20) have been shipped to the US from the Goa Plant II.

9. India Business

The company launched Telmichek–CT Tablets in the cardiac category. The company has Alogliptin combination with Metformin launch stated for later this year. Apixaban patent litigation case is scheduled for hearing before the Delhi High Court on September 8, 2020. The company’s legacy products accounted for 60% of the revenue. The number of MRs in India is around 2300.

In addition to Fevindo, Indoco has two more new products for launch in Covid Care range, i.e., Povidone Iodine Gargle and Immunity booster chewable tablets with Zinc, Vitamin C and Vitamin D.Fevindo-400 (Favipiravir) is an antiviral drug, effective against the RNA‐based influenza virus. The drug has been approved by DCGI in the treatment of Covid-19.

10. US Market

Revenue were flat QoQ at Rs. 268m. It received approval for Olanzapine tabs in 1QFY21 and plans to launch in 2QFY21. Its US partner received approval for Palonesetron injection, which was filed from Goa Plant II and it will be Launched in 2Q FY21 . Guided revenue of Rs1.5bn (vs. Rs560m in FY20) for FY21. It has around 18-20 ophthalmic products among the pending ANDA’s and it is in negotiation with three potential marketing partners and targeting for launch in FY 22.

11. Europe and EMS

Revenue grew 52% QoQ and declined 2% QoQ respectively. Guided for revenue of Rs2.25bn for Europe in FY21E (46% growth Y-o-Y) as it has a strong order book for next 6-8 months. Ivory Coast, French West Africa and Kenya have been major contributors for EM business.  

Disclaimer: The information provided on Shuchi Nahar’s Weekend Blog is for educational purposes only. The articles  may contain external links , references and compilation of various publicly available articles. Hence all the authors are given due credit for the same. All copyrights and trademarks of images belong to their respective owners and are used for Fair Educational Purpose only.

Twitter Handle: @shuchi_nahar

Comments

Post a Comment

Most Favorite Reads!

Ethanol - Demand, Production, Opportunities & Production Projections (Part-2)

-
Image
Rapid Increase in Ethanol Production Capacity Twitter Handle: @shuchi_nahar Two Different types of processes  to produce Ethanol To produce 684 crore liters of ethanol by the sugar industry by 2025-26, sugarcane equivalent to 60 LMT of surplus sugar would be diverted to ethanol. In the current sugar season, 2020-21 more than 20 LMT of sugar is estimated to be diverted. To produce 666 crore liters of ethanol/ alcohol from food grains by 2025-26, about 165 LMT of food grains would be utilized. At present damaged food grain availability is around 40 lakh tons in the country. In 2020-21 approximately 20 lakh ton maize is surplus FCI Rice is also sufficient in stock (266 LMT) and it will continue to remain robust as procurement of paddy/rice at MSP continues at expected levels. The country is producing sufficient food grains and sugar to meet the requirement for ethanol. Molasses-based distilleries have also been offered interest subvention to convert them to dual feed, to convert b...
Read more

Ethanol - Demand, Market Size, Opportunities & New Goverment Policies (Part-2)

-
Image
Ethanol production capacities, impact on Farmers, and Government Plans Twitter Handle: @shuchi_nahar Ethanol was rarely discussed in the country about 7-8 years ago. But now ethanol has become one of the major priorities of 21st century India. The focus on ethanol is having a better impact on the environment as well as on the lives of farmers. India’s requirement of ethanol for petrol blending will increase from 173 crore liters in 2019-20 to 1,016 crore liters in 2025-26. To enable the rollout of ethanol production across India, ethanol may be supplied from surplus to deficit states based on the requirements to ensure uniform availability of ethanol blends in the country. To achieve the Modi Administration’s E-20 blending goal by ethanol supply year (ESY) (December-November) 2025, India would need to procure approximately 11 billion liters (BL) of ethanol for blending with petroleum. As of November 2021, India’s concentrated ethanol production capacity totaled slightly above 6 bi...
Read more

Ethanol - Demand, Market Size, Opportunities & New Goverment Policies (Part-1)

-
Image
Ethanol - The next big tailwind story Twitter Handle: @shuchi_nahar Introduction Ethanol , also called ethyl alcohol, drinking alcohol, or simply alcohol is simple alcohol that is often abbreviated as EtOH. Ethanol production in India is mainly dominated by sugary feedstock, and C-heavy molasses available from sugar mills. Ethanol produced by fermentation of renewable food crops such as sugarcane, maize, wheat, sorghum, beet, and other starches is called bioethanol, and it is the eco-friendly alternative biofuel. The product is primarily used as a solvent in various industries such as: In addition, ethanol is gaining popularity as an efficient alternative fuel. It has significant penetration in the major end-use industries such as automotive, foods and beverages, chemicals, personal care and cosmetics, and pharmaceuticals. According to the reports, the global ethanol market is projected to grow at a robust CAGR of 4.5% to reach USD 117 Billion by the end of 2027. The primary factors fa...
Read more

Nutraceuticals - The Next Gem of Healthcare Sector

-
Image
     Nutraceuticals - The Next Gem of Healthcare Sector Shuchi.P.Nahar Twitter: shuchi_nahar What is Nutraceuticals? The term ‘nutraceuticals’ was firstly used in the late 1980s to describe food products that have a medicinal benefit. This fast-growing sector includes functional foods (such as vitamin-enriched products), nutritional supplements, sport drinks, and medically formulated foods.  Nutraceuticals and its Division Figure 1: The diagram showing the various divisions of Nutraceuticals  Scope Nutraceuticals is expected to play a central role in preventative healthcare. The logic seems simple - an ageing population gives rise to lifestyle-related diseases, whose impact can be lessened by making healthier choices earlier in life. This convergence of medicine, food and technology is likely to create a battleground in which food and pharma companies compete for dominance of the sector. Successful companies will have to hit the bullseye in six main areas: techn...
Read more

Laurus Labs - Result Update Q4FY21 & Full Year FY21

-
Image
Laurus Labs - Result Update Q4FY21 & Full Year FY21 Twitter Handle: @shuchi_nahar Laurus Labs Limited on 30th April 2021 announced its Q4FY21 and full-year results.  Laurus Lab performed extremely well consecutive in the 4th Quarter of FY21. The company did a robust growth in all three segments. Having a healthy order book for FY 22. Consolidated revenue for the quarter increased by 70% driven by growth in all the divisions. The company has been able to sustain its EBITDA margins, and profitability has also improved to Rs. 297 Crs. for the quarter. Generic API division showcased a robust growth of 61% YoY. Anti Viral segment recorded a robust growth of 70% YoY. Revenue Showcased a healthy growth of 102% YoY. The growth was led by higher LMIC Market volumes and increased volumes from North America and EU Commenced marketing of in-licensed products in the USA to leverage front-end capabilities. Custom Synthesis division recorded a strong growth of 35% YoY. Capacity Expan...
Read more